$ALLO
#BinanceAlphaAlert Allogene Therapeutics, Inc. (NASDAQ: ALLO) is a clinical-stage biotechnology company specializing in the development of allogeneic CAR T-cell therapies for cancer and autoimmune diseases. Founded in 2017 and headquartered in South San Francisco, California, the company focuses on off-the-shelf T-cell products to make immunotherapies more accessible and scalable than autologous alternatives. Key pipeline candidates include cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma and ALLO-316 for renal cell carcinoma, with ongoing trials in partnership with institutions like MD Anderson Cancer Center.
Financial and Market Snapshot (as of late November 2025):
Current Price: ~$1.46 (up 2.82% in recent session, but volatile with a beta of 1.60).
Market Cap: $289 million (small-cap territory).
Performance: Down 67% over the past 52 weeks and 56% YTD, reflecting broader biotech sector challenges like funding constraints and trial delays.
Short Interest: High at 15.28% of float (32 million shares), signaling bearish sentiment but potential for a squeeze.
Analyst Outlook: Strong Buy consensus from 8-11 analysts, with an average price target of $8.88 (implying ~608% upside). Recent ratings include Buys from H.C. Wainwright and Oppenheimer post-Q3 earnings, citing progress in ALPHA3 trial data.
Strengths: Innovative platform with potential to disrupt CAR T market (projected $10B+ by 2030); recent Q3 updates showed positive efficacy signals in lymphoma trials, boosting optimism. Risks: No revenue yet (pre-commercial stage), ongoing cash burn (~$96K/employee), and high short interest could amplify downside on misses. Verdict: High-risk, high-reward play for aggressive investors betting on clinical milestones in 2026; hold off if risk-averse.
For a visual of recent price action, here's a chart showing ALLO's 5-day hourly performance (data as of Nov 29, 2025):